Slides
Page 1
METROPOLIS METROPOLIS HEALTHCARE LIMITED Q1 FY27 Investor Presentation Diagnostics trusted by doctors and patients alike
Page 2
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Metropolis Healthcare Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the healthcare industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections. 01
Page 3
Metropolis - diagnostics that’s trusted by doctors and patients alike 35 ISO:15189 Accredited Labs 31 India / 4 Kenya 2 CAP Accredited Labs India 45 + Years of credible experience 4,500 + Tests & Profiles 209 Clinical Labs 5,000 + Service Network OUR VISION 12% CAGR revenue growth over the last 7 years 02 OUR BRAND PROMISE
Page 4
Q 1 F Y 2 7 Key Financial Highlights REVENUE INR 450 Cr 17% YoY EBITDA INR 113 Cr 27% YoY PAT INR 57 Cr 26% YoY EBITDA MARGIN 25.2% 210 bps PAT MARGIN 12.6% 90 bps ● Sustained demand momentum and increasing throughput from the expanded Lab & Center network enabled the company to outperform its growth guidance. ● Mid - teen revenue growth delivered despite no price hikes , demonstrating strong underlying demand and volume - led growth Q1FY27 EBITDA grew by 210 bps driven by operating leverage, automation, and continued process efficiencies. ● 03 NETWORK 5,003 8% YoY
Page 5
Key Performance Indicators B2C REVENUE INR 257 Cr 18% YoY B2B REVENUE INR 193 Cr 15% YoY TRUHEALTH INR 81 Cr 22% YoY SPECIALTY INR 178 Cr 17% YoY PATIENT VOLUME 3.7 Mn 10% YoY TEST VOLUME 7.8 Mn 11% YoY ● Double - digit patient and test volume growth , aided by deeper market penetration, the shift from unorganised to trusted chain labs and Tier - 3+ expansion. ● 17% growth in specialty testing revenues, led by successful upselling and Pan - India integration of the Core Diagnostics test menu. ● B2C powered by micro - marketing and brand pull ; B2B strengthened by service excellence and a wider clinician network. 04 Q 1 F Y 2 7
Page 6
Consistently delivering patient & test volume growth Patient Volume (in Mn) 3.35 Q1FY26 3.69 Q1FY27 +10% Test Volume (in Mn) 7.07 Q1FY26 7.83 Q1FY27 +11% Revenue Per Patient (INR) 1,151 Q1FY26 1,219 Q1FY27 +6% Revenue Per Test (INR) 546 Q1FY26 575 Q1FY27 +5% Q1FY27 Segment Contribution Specialty 40% Semi - Spl 25% TruHealth 18% Routine 17% Q1FY27 Segment Revenue Growth TruHealth 22% Specialty 17% Semi - Special 15% Routine 13% 05 Q 1 F Y 2 7
Page 7
Q 1 F Y 2 7 · C H A N N E L M I X B2C revenue up 18% YoY & B2B revenue up 15% YoY B2C · 57% B2B · 43% B2C +18% YoY Own, franchisee & rural centres TruHealth Growth +22% Specialty Growth +21% • Micro - marketing strategies and strong brand pull enabling volume - led growth • Tier - 3 and beyond expansion widening B2C reach and patient acquisition • Digital, app and AI - led initiatives improving TruHealth conversion • Premiumisation through Vitals, Consult and ECG offerings B2B +15% YoY B2B labs, hospitals, government, corporate & clinical trials TruHealth Growth +23% Specialty Growth +15% • Improving business quality, service excellence and ease of doing business • Driving stronger specialty - led growth • Widening clinician and institutional network 06 MetLink – Flagship Franchisee Partner Engagement Programme B2B Partner training and Engagement
Page 8
Q 1 F Y 2 7 R E V E N U E G R O W T H TruHealth & Speciality TruHealth Strong revenue momentum, premium mix & digital acceleration GROWTH 22% CONTRIBUTION 18% Radiology - integrated wellness packages grew 40%+ through range optimisation and focused upselling. Premium TruHealth packages grew 50%+, led by doctor consult, vitals and ECG - led extensions. Launched AI - enabled personalised nutrition and TruHealth Mind & Body for cognitive wellness. Introduced dedicated Wellness Zones at marquee centres for consultative wellness delivery. Speciality GROWTH 17% CONTRIBUTION 40% ● ● ● ● 07 Wellness Zone at Key Centres for Consultative TruHealth Series of Genomics Symposiums across the country for Specialist Connect ● ● ● ● ●
Page 9
Q 1 F Y 2 7 · R E A C H Diversified revenue contribution across geographies Map not to scale; for illustrative purposes only. By Region West 50% South 27% North 18% East 6% By City Tier Tier I 67% Tier III 26% Tier II 7% ~750 ~25% 18% North India contribution, up from 17% Revenue contribution of domestic revenue only. 08 Region Growth West 14% South 14% North 19% East 11% Tier Growth Tier I 11% Tier II 14% Tier III 25%
Page 10
I N F R A S T R U C T U R E Building a scalable, efficient network Laboratory Network 125 FY21 161 FY22 175 FY23 199 FY24 209 Q1FY27 Over the last 5 years 87 labs added to the network. In Q1FY27, consolidated 7 labs with acquired entities Service Network 2,555 FY21 3,134 FY22 3,675 FY23 4,150 FY24 4,536 FY25 5,026 FY26 Over the last 5 years 2,471 service points added ~750 295 service points added in Q1FY27 with rationalisation of 318 non - productive centres 09 210 FY25 212 FY26 5,003 Q1FY27 24:1 Centre: Lab Ratio improved over 21:1 LY.
Page 11
Q 1 F Y 2 7 Consolidated Profit & Loss Statement Profit & Loss Statement Q1FY27 Q1FY26 Y - o - Y Revenue from Operations 450.2 386.1 16.6% Total Cost 337.0 296.9 EBITDA 113.2 89.1 27.1% EBITDA Margin (%) 25.2% 23.1% 210 bps Depreciation 32.4 30.8 Other Income 5.1 7.5 EBIT 86.0 65.8 30.6% Finance Cost 8.3 4.6 Profit Before Tax 77.7 61.2 26.9% Current Tax 20.8 16.0 Profit After Tax (PAT) 56.9 25.8% PAT Margin (%) 12.6% 11.7% 90 bps 10
Page 12
S T R A T E G Y Metropolis 3.0
Page 13
M A R K E T C O N T E X T The Indian diagnostics industry Market size — US$ bn (~11% CAGR to 2034E) ~US$11 bn India diagnostic labs market size, 2025 ~11% Projected CAGR, 2025 – 2034E ~15% Organised chains’ share — rest is fragmented >60% Share of mortality from non - communicable diseases — drives recurring testing What's powering the shift to organised • Accreditation, quality and consistency (NABL) building doctor and patient trust • Home sample collection, digital reports and online booking widening access • Deeper Tier 2/3 penetration and rising preventive & wellness testing Source: IMARC Group — India Diagnostic Labs Market (2025); Ministry of Health & Family Welfare. Figures are industry estimates, rounded. 11.0 15.1 21.0 28.5 2025 2028E 2031E 2034E Market structure by provider (2025) – Highly fragment market 48% 37% 15% Standalone / unorganised labs Hospital-based labs Organised chains 12
Page 14
Strong Governance M E T R O P O L I S 3 . 0 Key pillars of the strategy - poised to grow further 1 Leading with Technology Pioneer AI and digital innovation to redefine diagnostics and elevate customer experience, building on our proven strengths in quality, precision, and operational excellence to shape the future of healthcare. 4 Brand Promise Build and protect trust by empowering consumers, clinicians, and employees with precise, compassionate care, reinforced by ethical practices, operational excellence, and a culture grounded in accountability 2 Differentiate Scientifically Lead with scientific excellence and uncompromising diagnostic quality, setting industry benchmarks through rigorous standards, expert - led interpretation, and sustained investment in medical innovation. 3 Consistent, Profitable Growth Scale the core business sustainably and profitably while expanding strategic adjacencies, driving operating leverage, prudent capital allocation, and resilient long - term shareholder value 13
Page 15
T E C H N O L O G Y Driving business growth through digital transformation 14 THE TECHNOLOGY STACK Enhanced Productivity Second - generation Point of Sale platform — Registration & Invoicing Platform 2.0. Rapid Scalability Partner Portal for end - to - end partner life - cycle management and engagement. Future - Ready Architecture & AI Customer Data Platform for a 360 ° customer view, using AI to personalize experiences. Improved User Experience Sales CRM with customizable CPQ to manage dynamic pricing. Data Security & Privacy Enterprise - grade security with DPDP - compliant patient data handling. A UNIQUE HEALTHCARE TECHNOLOGY STACK DELIVERS Personalization Cross-Channel Consistency Efficient Patient Service Case Management Relationship Management Opportunity Management DPDP Efficient Patient Registration Accurate Billing & Pricing Reporting & Analysis 360° Customer View
Page 16
S C I E N C E · R E S E A R C H · A C A D E M I C S Scientifically driven, with a strong focus on quality 36 new tests added in Q1FY27 (incl. CDP) 347 tests added in FY26 including integrating Core menu 99% EQAS external quality assurance score 99.99% report accuracy 100% labs under CAP / NABL / KENAS or benchmarked Scientific Expansion • New tests across Oncology, Nephrology, Gynecology and infectious & chronic disease segments. • NGS / molecular genomics growing, driven by in - house testing and AI - enabled genetic reporting. • Centres of Excellence: Women & Child Health and Oncology. Education & Skilling • Metropolis Institute of Laboratory Education & Skilling (MILES). • UGC - certified MedTech courses launched with university collaboration. • Aligned with the government focus on upskilling trained healthcare professionals. 1st in Industry to Medical Advisory Board • Internal & external i - MAB with 60+ subject - matter experts. • Focus on scientific differentiation and quality excellence. • Centres of Excellence pipeline across 3 specialties. 15
Page 17
S U S T A I N A B I L I T Y Metropolis ESG goals & key plans E Emissions for a greener tomorrow Carbon neutrality by 2043 · 45% lower emissions intensity & 50% less plastic by 2030 · zero waste & water neutrality by 2043. S Quality, safety, diversity & well - being B2C NPS @ 90 by 2028 · 100% OHS awareness & training · gender - neutral workforce by 2028 · 6 lakh direct beneficiaries by 2043. G Integrity, security & compliance Zero data breaches · patient - data protection under ISO 27001 & ISO 27701 · zero instances of non - compliance. K E Y E S G P L AN S Emissions & Energy 10% energy reduction via renewables · sub - metering solutions · replace end - of - life assets · reduce air miles by 2%. Water & Waste Management 5% water reduction via conservation · rainwater harvesting · 10% less plastic with biodegradable alternatives · paperless reporting. Employee Recruitment, Development & Retention Career 2.0 to increase gender diversity · strengthen L&D programmes · reduce attrition through Early Warning Signals. Occupational Health & Safety Raise safety awareness among employees · conduct safety audits for compliance checks. Patient Privacy & EHR 100% training on information security & data privacy · sustenance audits by BSI to maintain ISO 27001 & ISO 27701. Community Development MedEngage, Too Shy to Ask (TSTA) and Preventive Healthcare CSR projects. Risk Management Annual assessments of the Risk Register per ERM · track mitigation plans for identified high - risk areas. Quality of Care & Patient Satisfaction Aim for B2C NPS over 90% by addressing detractors · resolve 85%+ of complaints within 24 hours. Board Governance, Ethics & Compliance Ongoing amendment of policies from corporate - law and organizational perspectives · zero non - compliance · board diversity. 16
Page 18
C O R P O R A T E S O C I A L R E S P O N S I B I L I T Y CSR at Metropolis — creating a positive impact ADOLESCENT REPRODUCTIVE SEXUAL HEALTH (ARSH) • 1.3 lakh+ adolescents reached through life - skills and reproductive health education. • 6,300+ Kishori Manch groups and 2,900+ Girl Champions empowered communities. • 8,120+ girls counselled and 2,030+ healthcare referrals facilitated. • 2.9 lakh+ organic app downloads through the Too Shy To Ask platform. MEDENGAGE • 320+ scholarships awarded to aspiring medical students. • 89+ research grants supported across India. • Presence across 44 aspirational districts. • Advancing medical education through scholarships, research and mentorship. • Regular MedTalks and webinars with SMEs to groom young medical talent, reaching over 1 lakh views. Preventive Healthcare • 40,000+ preventive health screenings conducted for diabetes and anaemia. • 520 TB patients supported with nutritional assistance. • 100% treatment adherence achieved among supported TB patients. • 88% beneficiaries showed improvement in BMI/weight. 17 Empowering Adolescents with Health and Life Skills Nurturing young medical talent PREVENTIVE HEALTHCARE Strengthening Community Health
Page 19
‘ P R O M O T E R L E D — P R O F E S S I O N A L L Y D R I V E N ’ A dynamic leadership team for the next level of growth Ameera Shah Promoter & Executive Chairperson Surendran Chemmenkotil Managing Director Dynamic Leadership Team for Next Level of Growth Dr. Sushil Shah Founder & Non – Executive Non - Independent Director Sameer Patel Chief Financial Officer Avadhut Joshi Chief Business Development Officer Diya Suri Chief People Officer Dr. Kirti Kazi Chief Scientific & Innovation Officer Mohan Menon Chief Marketing Officer Bhoopendra Rajawat Chief Business Officer West and East Kannan Alangadan Chief Business Officer South Pinakin Shah Chief Information Officer Glen Menezes Group Head – Customer Success Umesh Rai Head - Emerging Business Ravikumar Kartha Group Head - Internal Assurance and Business Excellence Dr. Monika Prabhakar Group Head - Lab Operations 18
Page 20
R E C O G N I T I O N Recent awards & accolades Dec’25 Ameera Shah — Most Powerful Women in Business by Business Today, 2025. Sep’25 Dr Sushil Shah & Ameera Shah — Hurun India Family Business Excellence Award, 2025. Sep’25 Ameera Shah — Influential Leader of India Award 2025 by Marksmen Daily. Best Diagnostic Chain of the Year 2026, FE Healthcare Excellence Awards. Gold, Best Social Impact in Healthcare 2026, FE Healthcare Excellence Awards. Best Healthcare Brands Award, ET Edge, 2026 May’26 Excellence in Laboratory Quality Award – BW HealthcareWorld May’26 Excellence in Molecular Diagnostics – BW HealthcareWorld May’26 Excellence in Women’s Health Diagnostics – BW HealthcareWorld Jul’26 Ameera Shah — Most Powerful Woman in Business by Fortune India, 2025. Mar’26 Surendran Chemmenkotil – Top Transformative Healthcare Leaders of Maharashtra 2026. Mar’26 Ameera Shah - Most Influential Women in Healthcare 2026 – by BW Healthcare World Jan’26 Ameera Shah – Woman Healthcare Leader of the Year 2025 – by Voice of Healthcare Sep’25 Jun’25 Most Innovative Organizations Award by ET Now for the year 2025. Jun’25 Best Healthcare Brands Award by ET Edge for the year 2025 Gold, Best Diagnostic Chain of the Year 2025, FE Healthcare Excellence Awards Ameera Shah - 100 Most Influential Women 2026 – by BW Businessworld Mar’26 Dr Sushil Shah and Ameera Shah felicitated with the Hurun India’s Family Business Excellence Award for the year 2025. Jun’25 Jul’26 Jul’26 Jun’26 19
Page 21
M E T R O P O L I S For further information, please contact COMPANY Metropolis Healthcare Ltd. Mr. Kamlesh Kulkarni INVESTOR RELATIONS ADVISORS Strategic Growth Advisors Pvt. Ltd. Mr. Sagar Shroff / Mr. Shogun Jain 20